The Peptide NewsroomPeptide research, industry and supply-chain headlines

Us Weekly Pitches Calocurb as a GLP-1 Alternative, But the Numbers Are the Brand's

Topic card: glp-1

A shopping feature published by Us Weekly promotes Calocurb, a three-ingredient capsule pitched at readers who want appetite suppression without an injectable GLP-1 prescription. The piece carries an affiliate disclosure at the top, which is the first thing worth knowing about the figures further down.

The formula is Amarasate, described as a New Zealand-derived bitter plant extract, plus rosemary leaf extract and vegetable oil. Amarasate is the active piece: Us Weekly says it targets bitter taste receptors in the small intestine, which stimulates GLP-1 and other gut hormones and slows gastric emptying so food stays in the stomach longer.

Bitter receptors, familiar hormone

That mechanism is genuinely interesting, because it is the same hormonal pathway the injectable drugs work on, approached from the opposite end. Rather than supplying a GLP-1 analog, the pitch is that a bitter compound prompts the gut to release more of its own.

It is also the point where a supplement story usually outruns its evidence. Stimulating a hormone and producing a measurable change in body weight are different claims, and only one of them is easy to demonstrate.

Where the numbers come from

Us Weekly reports that the capsules can reduce hunger by 30 percent, cravings by 40 percent and calorie intake by 18 percent, and attributes all three figures to the brand. No study is named, no sample size is given, and no comparison group appears anywhere in the article.

Three percentages without a denominator are marketing copy, not results. The rest of the supporting material is customer reviews quoted from the retailer, which is not evidence of anything beyond what those customers wrote.

What the brand recommends

The article relays a ramp-up schedule from Calocurb: one capsule an hour before a meal for the first two days, building to two capsules twice daily after day five. Mild digestive discomfort in the first few days is described as expected and not persistent.

Bottom line

The honest version of this story is that a plant extract with a plausible gut-hormone mechanism is being sold on numbers its own manufacturer generated. Us Weekly concedes the product is not a miracle pill and still requires diet and exercise, which is the most reliable sentence in the piece.

Source: Us Weekly. Read the original.

Filed under: glp-1

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

GLP-1 Drugs Linked to Small Lumbar Bone Density Drop, But Hip BMD Held Steady

A meta-analysis in Bone pooled 11 placebo-controlled trials and reported a small reduction in lumbar spine bone mineral density with GLP-1 receptor agonists, alongside a rise in the resorption marker CTX. The authors found no eligible placebo-controlled trials at all for semaglutide 2.4 mg/week or tirzepatide.

California Clinic Pitches a Hollywood Peptide Stack, But Says It Is Not Validated

A press release from California Trim Clinic promotes an article on NAD+, copper peptides and a tirzepatide-based Hollywood Glow Stack. Its own disclaimers say the combination is not FDA-approved or clinically validated.

Combined SGLT2 and GLP-1 Therapy Linked to Fewer Kidney Events in Large CKD Records Analysis

A TriNetX records analysis of 178,930 chronic kidney disease patients found combined SGLT2 inhibitor and GLP-1 receptor agonist therapy associated with lower risks of major kidney events and death than SGLT2 inhibitor alone. The cardiovascular endpoint showed no significant difference, and the authors call for further study.